Ascendis Pharma Reports Third Quarter 2026 Financial Results
Q3 2026 product revenue of €366 million (+89% Y/Y), comprising €291 million for YORVIPATH®, €59 mill
Related stories
BioHarvest Sciences Cuts FY2026 Sales Guidance to $32M-$33.5M
BioHarvest Sciences lowered its FY2026 sales guidance from $37M-$40M to $32M-$33.5M, versus the $37.461M estimate.
M impact | EARNINGS | Nov 12, 2026, 03:03 PM UTC
UPDATE 1-Italy's Fincantieri lifts 2026 core profit guidance after rising EBITDA
UPDATE 1-Italy's Fincantieri lifts 2026 core profit guidance after rising EBITDA Adds share move and
L impact | EARNINGS | Nov 12, 2026, 02:54 PM UTC
TSX Falls on Tech and Commodity-Linked Stocks Losses
The S&P/TSX Composite Index fell about 0.5% to hover below 36,500 on Thursday, tracking the US stock market following key earnings. The tech sector was pressured by a plunge in Nvi
H impact | EARNINGS | Nov 12, 2026, 02:53 PM UTC
Yeti Lowers Full-Year Outlook After Third-Quarter Sales Miss
Yeti lowered its full-year outlook after third-quarter sales missed Street views.
M impact | EARNINGS | Nov 12, 2026, 02:45 PM UTC
BEYOND AIR SHARES FALL 23% TO $2 AFTER Q2 RESULTS
L impact | EARNINGS | Nov 12, 2026, 02:37 PM UTC
Tenable Integrates Anthropic AI Into Platform, Reports Metrics and 2026 Guidance
Tenable integrated Anthropic’s Claude Mythos into its Tenable One Exposure Management Platform for the new Tenable One Adversary View. It added 413 enterprise platform customers an
M impact | EARNINGS | Nov 12, 2026, 02:33 PM UTC